Conavi Medical Reports Fiscal Q2 2025 Interim Results and Operational Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 30 2025
0mins
Source: Newsfilter
Funding and Product Development: Conavi Medical Corp. has successfully raised $20 million in financing to support the development and regulatory submission of its next-generation Novasight Hybrid™ System, with plans for a U.S. commercial launch in H1 2026.
Regulatory and Clinical Validation: Recent updates to U.S. intracoronary imaging guidelines by leading medical organizations endorse the use of intravascular imaging, which aligns with Conavi's technology, positioning it favorably for market entry as they prepare for FDA submission in Q3 2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
